Pharma & Bio
Technology
Olix Pharmaceuticals, Inc. Shaken for Fourth Straight Day Following Clinical Trial Setback… Will It Resubmit OLX301A? [Bio Spotlight]
On the 27th, the domestic stock market rebounded for the first time in a while, but it was a “Black Tuesday” for major biotech stocks. The KOSPI closed at 5,638.34, up 3.09% from the previous trading …
- 2026-10-29 07:42:03
- NA EUN-KYUNG
Lifestyle
[Exclusive Interview] Biohaven: “BHV-1530 Expected to Be ‘First in Its Class,’ Surpasses Lilly’s Compound”
“The FGFR3-targeted antibody-drug conjugate (ADC) ‘BHV-1530 (AMB302)’ has demonstrated confirmed tumor responses in urothelial carcinoma and head and neck cancer. This can be considered a significant …
- 2026-10-29 07:37:02
- Kim Jinsoo
Lifestyle
Kim Jeong-guk, CEO of NeoKenBio: “Potential for Medical Cannabis Materials Confirmed in the U.S.... Revenue to ‘Triple’”
“We expect this year’s revenue to reach 15 billion won (3 billion won domestically, 12 billion won overseas), more than tripling last year’s figure. This is the result of having firmly demonstrated th…
- 2026-10-29 06:26:02
- YU JIN-HEE
Technology
Matika, Which Invested 150 Billion, Sees Increased Orders but Revenue Remains Uncertain [ChaBio Deep Seek ④]
Matica Biotechnology (hereinafter “Matica”), which Cha Bio Group has been developing as a forward base for contract development and manufacturing (CDMO) of cell and gene therapies (CGT) in the U.S., h…
- 2026-10-29 06:06:02
- KIM SAE-MI
Lifestyle
[ESMO 2026] Vaxcell-Bio Therapeutics: “CAR-MIL Shows 100% Survival Rate in Animal Trials… Compared to J&J’s Carvikt”
It has been confirmed that “VCB-1201,” a cell therapy for multiple myeloma currently under development by Vaxcell-Bio Therapeutics(323990), achieved a 100% survival rate over 120 days in preclinical a…
- 2026-10-28 11:01:02
- Kim Jinsoo
Lifestyle
Lee Sang-hyun, CEO of OSCOTEC Inc.: "2.5 billion investment yielded 1.5 trillion in L/O results, proven by new drug"
“A 2.5 billion won investment led to a global technology export deal worth up to 1.53 trillion won.” Lee Sang-hyun, CEO of OSCOTEC Inc., began by recounting the story of “ADEL-Y01,” an Alzheimer’s tre…
- 2026-10-28 09:02:02
- KIM JI-WAN
Lifestyle
Professor Yoon Jae-ho of Seoul St. Mary’s Hospital: “Anbalcel Confirms Efficacy in ALL… Sustaining That Efficacy Is Key” [Expert Insight]
“Anvalcel demonstrated excellent safety without any fatal side effects in its Phase 1 trial for adult leukemia. Patients receiving the optimal dose showed initial treatment responses and minimal resid…
- 2026-10-28 07:31:02
- Kim Jinsoo
Technology
A Breakthrough After the BMS Suspension… Lee Seung-ju, CEO of Orum: “We Will Deliver Results with a New Payload”
#Orum Therapeutics, Inc., which halted development of a blood cancer drug candidate after selling it to BMS, is seeking a breakthrough through in-house clinical trials of a follow-up drug and the deve…
- 2026-10-28 07:22:02
- NA EUN-KYUNG
Technology
ROKIT HEALTHCARE Inc. Blames Distributors for FDA Warning; Uncertainty Over U.S. Operations Rises Without Therapeutic Approval
#ROKIT HEALTHCARE Inc. explained that the U.S. Food and Drug Administration (FDA) warning letter regarding its product “APLICOR 3D” stemmed from “excessive promotion” by a local distributor. However, …
- 2026-10-28 07:11:02
- KIM SAE-MI
Business·Industry
[ESMO 2026] Lim Yu-ju, Medical Director at Lunit Inc.: “Using AI to Uncover Data by Cancer Type... Expanding to New Drug Development”
“The technology for distinguishing cells was developed several years ago. We are now continuing our research on how to interpret that information.”Lim Yu-ju, Medical Director at Lunit Inc.(328130), ex…
- 2026-10-28 07:06:02
- Kim Jinsoo
PHARM EDAILY
Shorts